During the 2018 annual American Society of Hematology (ASH) meeting, I was hosted by CLL Society and Dr. Brian Kauffman to discuss recent research I had presented at that meeting on the economic impact of using venetoclax versus chemotherapy or chemoimmunotherapy for patients with CLL. This was a poster presentation that generated a lot of interest from various stakeholders. At the time of this interview, I was a VP and CMO at Cardinal Health Specialty Solutions.
Menu